Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
about
Melanoma-associated leukoderma - immunology in black and white?Cancer vaccinesRecommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyCTLA4 blockade broadens the peripheral T-cell receptor repertoireTumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artHighlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.Trends in cancer immunotherapyEctopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Therapeutic cancer vaccines: are we there yet?Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses.IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinomaVirally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.Enhancement of dendritic cells as vaccines for cancerImmunotherapy for melanoma: current status and perspectives.An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Update on vaccine development for renal cell cancer.Lessons learned from cancer vaccine trials and target antigen choiceNew insights on adenovirus as vaccine vectors.The evolving role of dendritic cells in cancer therapy.Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.Directing dendritic cell immunotherapy towards successful cancer treatment.Dendritic cells: are they clinically relevant?Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Engineering dendritic cells to enhance cancer immunotherapy.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.NK cells: key to success of DC-based cancer vaccines?Immune biomarkers: how well do they serve prognosis in human cancers?Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy.Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma.
P2860
Q26850001-A14B0F8B-4CDB-4457-8A21-3493603814B5Q27024438-4326AD98-DC69-4BB9-9002-36EDB7E2265BQ28744503-CBAF7EA6-8F95-435F-820B-4CDE00C7DF4CQ30426385-2D35EBF5-48D4-48DD-8671-3D9158571553Q30438965-78A24DDF-14AB-41E5-94FC-7C51AF19631EQ33560753-2CBD05AF-6142-4D8D-ABBB-4E39FA7BEEC3Q33907628-7926FF28-FEFF-419E-AACD-E568CBEBC368Q33913101-62ACE4EE-7374-4A52-8865-E2BE4A4A3665Q34052702-BAF6A713-24AC-46E6-B047-0D703F88F0EBQ34066925-4232B421-DFAA-4D00-A3E9-F58D9473EB43Q34627677-3970180F-88EE-4FE3-B806-42AD1E12316AQ34661815-90ED5F63-C87A-4291-84E9-A2707344B111Q34786691-D464095F-8F59-4309-8B4E-8C12FD58834DQ35088691-162439F1-3E11-4902-A443-9C8D1FF5B212Q35156105-EB3BAF14-172F-4395-BA7A-C0EEC072A09BQ35871590-69DD778E-DEE7-4404-94B0-CAEF32DAA6B0Q35883106-A7BAD97C-7F8F-48BD-9D91-53257E54B676Q36057449-9FF290A9-D338-4FF5-8E6A-9AB6544E9257Q36209210-C15E77A9-2208-4607-B7A3-C46CC12B0941Q36453216-32A75D39-21D8-4E3D-8927-83815CFAB447Q36476387-41CB5FEE-BAAE-47E8-ABA1-A0A062B8BC42Q36547213-D85C450B-D1A0-4688-9209-2FA312AF6B99Q36567448-7A053643-F1C9-457E-B1D0-9E4B822FBD5CQ36989720-BCE30BFE-BAD1-424E-BE3B-C2D8A4850D86Q37033762-8859DCD9-4213-4DEA-9077-394E657ED2D4Q37513550-B09CF7B6-7583-4B5A-BE63-1E9D402E9574Q37687418-D998C2B9-EDE0-489B-A962-3933D9C05856Q37727967-AA822648-80B0-4397-B066-93E0DD500D73Q37754014-77E67FCD-014F-4512-ADCF-D946AD2376D9Q37778692-B7AC5979-478F-4AD9-B31D-66D7969689F5Q37800934-EC188769-4464-4C8C-ACA2-F2F16EBCD2B7Q37820489-EE4FFFF7-2B04-4154-BACD-1F19BE52D6BAQ37862064-3F0125D0-EC58-4512-BAB5-86B787FA99ECQ37952804-A855FF83-A27F-43B1-B6CD-F6127B226EBAQ37974160-9D2F2F51-703E-44CE-B839-AA16CD7E0684Q37989571-7639FC5E-575E-471C-BFBB-8E61A61AC6C3Q38036202-A782B2E1-2A5A-4DF0-B160-17385FD2AAF3Q38262757-899A6CED-65B1-414C-8B5F-999B83278A62Q39037222-8E4156F9-6104-418D-B5EE-51F2666B643DQ39575914-654DFA1C-6967-4737-8C09-2D153E11D29A
P2860
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
@en
type
label
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
@en
prefLabel
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
@en
P2093
P2860
P1476
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
@en
P2093
Antoni Ribas
Begonya Comin-Anduix
Denise K Oseguera
Douglas M Potter
Elizabeth Seja
James S Economou
Jin-Quan Yang
John A Glaspy
Lazar Vujanovic
P2860
P304
P356
10.1097/CJI.0B013E31816A8910
P577
2008-04-01T00:00:00Z